Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.
暂无分享,去创建一个
[1] C. Boshoff,et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer , 2000, British Journal of Cancer.
[2] G. Tortora,et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. , 2000 .
[3] T. Dorai,et al. Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. , 1994, Molecular pharmacology.
[4] S. Mutsaers,et al. Cytokine regulation of mesothelial cell proliferation in vitro and in vivo. , 1997, European journal of cell biology.
[5] J. Mestan,et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.
[6] H. Kindler,et al. Malignant pleural mesothelioma , 2000, Current treatment options in oncology.
[7] R. K. Bright,et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours , 1999, British Journal of Cancer.
[8] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[9] H. Strander,et al. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. , 1998, Anticancer research.
[10] T. H. van der Kwast,et al. EXPRESSION OF PLATELET‐DERIVED GROWTH FACTOR (PDGF) AND PDGF RECEPTORS IN HUMAN MALIGNANT MESOTHELIOMA IN VITRO AND IN VIVO , 1996, The Journal of pathology.
[11] N. Vogelzang,et al. Chemotherapy in malignant pleural mesothelioma. A review. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Casalini,et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma , 2001, The Journal of pathology.
[13] T. H. van der Kwast,et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. , 1991, Oncogene.
[14] E. Gabrielson,et al. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. , 1987, Cancer research.
[15] G. Tortora,et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.